If you are looking to add some ASX 200 stocks to your portfolio this week, it could be worth checking out the two in this article.
That’s because Bell Potter believes they could be dirt cheap at current levels. Here’s what the broker is recommending:
Pro Medicus Ltd (ASX: PME)
The first ASX 200 stock that Bell Potter is bullish on is Pro Medicus.
It likes the health imaging technology company due to favourable industry trends and the quality of its Visage platform.
The broker explains:
The company continues to announce new contract wins on a regular basis as the drivers of interest in its product offering remain firmly in place. The entire radiology industry is headed to cloud based (off premises) archiving. Put simply, the Visage 7 viewer, Workflow and Archive are the fastest and most advanced tools for the retrieval and viewing of large radiology files.
The platform is immensely scalable and relatively easily installed, providing it with a sustainable competitive advantage over the likes of peers Intelerad, Sectra, Philips and GE Healthcare. The company is conservatively managed and well owned by large institutional investors while the two founders continue to have a controlling stake.
Bell Potter has a buy rating and $240.00 price target on its shares. This implies potential upside of 100% for investors over the next 12 months.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another ASX 200 stock that Bell Potter is recommending to clients is Telix.
It is a radiopharmaceuticals company that had a tough time in 2025 with US FDA rejections. However, the broker appears to believe that 2026 could be different, potentially making now a good time to invest.
Bell Potter commented:
We are confident regarding the approval in CY 2026 of Zircaix following resubmission of the Biological License Application (BLA). The FDA rejected the original BLA due to CMC (chemistry manufacturing & control) matters at Telix’s manufacturing partner. There were no matters related to safety or efficacy. We expect the market for Zircaix once approved will be in excess of US$500m.
The product has been included in guidelines for disease management in the US and Europe and continues to be available in the US under the expanded access program. Elsewhere, sales of Iluuccix/ Gozellix in the PSMA franchise continue to grow and were recently boosted by the refresh on the pass through pricing.
The broker has a buy rating and $19.00 price target on Telix’s shares. This suggests that they could rise approximately 50% from current levels.
The post Bell Potter says these ASX 200 stocks could rise 50%+ appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- The best ASX shares to invest $1,000 in right now
- Why buying ASX shares in March could supercharge your wealth
- 3 ASX 200 stocks screaming higher in this week’s sinking market
- Morgans says these ASX 200 shares could rise 120%
- Could Telix shares be a millionaire-maker stock?
Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.